Compare MPV & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | NYXH |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 161.9M |
| IPO Year | N/A | 2021 |
| Metric | MPV | NYXH |
|---|---|---|
| Price | $16.71 | $1.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 11.8K | ★ 501.1K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | $9.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.65 | $1.26 |
| 52 Week High | $21.00 | $8.59 |
| Indicator | MPV | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 35.28 |
| Support Level | $16.51 | $1.26 |
| Resistance Level | $17.53 | $1.70 |
| Average True Range (ATR) | 0.49 | 0.16 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 49.06 | 88.89 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.